In contrast, dipeptidyl peptidase 4 inhibitors (DPP‐4 inhibitors), GLP‐1 agonists, sodium‐glucose cotransporter‐2 inhibitors (SGLT2), and thiazolidinediones were prescribed less in persons with T2D (4.6%, 3.3%, 0.7%, and 1.2%, respectively). The gene discussed is DPP4; the disease is type 2 diabetes mellitus.